Altered PTEN expression; A diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium

Department of Pathology, Mirza Koochak Khan Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Diagnostic Pathology (Impact Factor: 2.6). 11/2009; 4(1, article 41):41. DOI: 10.1186/1746-1596-4-41
Source: PubMed


Different molecular alterations have been described in endometrioid endometrial carcinoma (EECA). Among them the most frequently altered is loss of the PTEN protein, a tumor suppressor gene. The purpose of this study was to evaluate the expression pattern of PTEN gene in normal, hyperplastic and neoplastic endometrium.
In a study in a referral gynecologic hospital in Tehran, Iran, immunohistochemical (IHC) evaluation of PTEN was performed on 87 consecutive specimens to the following three groups; group A- normal proliferative endometrium(n = 29); group B- hyperplastic endometrium [including simple hyperplasia without atypia(n = 21) and complex hyperplasia with atypia (n = 8)] and group C- EECA(n = 29). Immunostaining of cells was analyzed by arbitrary quantitative methods according to both slide's area staining and intensity of color reaction.
PTEN immunoreactivity was present in all normal proliferative endometrium, all simple hyperplasia, 75% of atypical complex hyperplasia and in 48% of EECA (P < 0.001). The intensity of PTEN reaction was significantly higher in group with proliferative endometrium than hyperplastic endometrium and EECA (P < 0.001).
PTEN expression was significantly higher in cyclical endometrium than in atypical hyperplasia and endometrioid carcinoma.

Download full-text


Available from: Narges Izadi-Mood, Jul 14, 2015
  • Source
    • "Additionally, VEGF in uteri was also co-expresses with PD-1 (Figure 5D), suggesting that PD-1 signaling inhibits epithelial cell proliferation potentially through a reduction of VEGF secretion, in addition to direct prevents epithelial proliferation by cross-reacts with PD-Ls. However, the expression of PTEN, a tumor suppress gene, were significantly higher in cyclical endometrium than in atypical hyperplasia and endometrioid carcinoma, indicated that PTEN involves in the pathogenesis of endometrial hyperplasia [23]. On the other hand, CyclinD1, a cell -cycle regulator, exhibited a promising potential to predict the prognosis of patients with endometrial carcinoma [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Programmed death-1 (PD-1, Pdcd1)-deficient mice develop different types of autoimmune diseases depending on the mouse strain but its role in uterus development has not been reported. In this study, the expression of PD-1 and its ligands, PD-L1 and PD-L2, in uterine tissues from aged WT mice in a 129svEv-Brd background was analyzed by immunohistochemistry and the uterine morphology between WT and PD-1-/- mice was compared by hematoxylin and eosin staining. The aged PD-1-/- female mice in a 129svEv-Brd rather than Balb/c background develop endometrial hyperplasia. H&E staining showed an increase in the number of glands, neovascularization and an extremely large luminal cavity in aged PD-1-/- uteri. Immunohistochemical assay showed that the expression of PD-1 was observed in glandular/luminal epithelium and cells infiltrating the stroma. Fluorescent double staining demonstrated that PD-1 expresses on CD68+ macrophages, CD3+ T cells, CD16+ monocytes, CD56+ NK cells and CK-18+ epithelial cells, respectively. Additionally, PD-1 co-expresses with vascular endothelial growth factor (VEGF), and PD-1 deficiency resulted in an accumulation of glandular/luminal epithelium derived VEGF, which accelerates the expression of the proliferation-associated protein, proliferating cell nuclear antigen (PCNA), and thus potentially lead to epithelial proliferation in aged PD-1-/- uteri. These findings showed that PD-1 deficiency augments luminal epithelial cell proliferation probably through induced VEGF secretion, suggesting PD-1 plays an important role in controlling the growth and differentiation of the uterine epithelium. Virtual Slides The virtual slide(s) for this article can be found here:
    Diagnostic Pathology 05/2014; 9(1):97. DOI:10.1186/1746-1596-9-97 · 2.60 Impact Factor
  • Source
    • "Type I EC frequently exhibits altered PI3K/PTEN/AKT/ mTOR signal pathway [7] [8] [9] [10] [11]. Type II cancer predominantly shows mutations in p53 [12] and epidermal growth factor receptor 2 (HER-2) overexpression [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/acquired drug resistance and unexpected side effects on normal tissues. New studies that aim to target both genetic and epigenetic alterations (noncoding microRNA) underlying malignant properties of tumor cells and to specifically attack tumor cells using cell surface markers overexpressed in tumor tissue are emerging. More importantly, strategies that disrupt the cancer stem cell/epithelial-mesenchymal transition-dependent signals and reactivate antitumor immune responses would bring new hope for complete elimination of all cell compartments in endometrial cancer. We briefly review the current status of molecular therapies tested in clinical trials and mainly discuss the potential therapeutic candidates that are possibly used to develop more effective and specific therapies against endometrial cancer progression and metastasis.
    06/2013; 2013(1):130362. DOI:10.1155/2013/130362
  • Source
    • "The uterine body type II cancers are histogenetically distinguished from type I cancers with a background of glandular hyperplasia which is in association with the genetic alterations represented by PTEN inactivation [1]. Tumor development of uterine body serous adenocarcinoma, categorized as the type II group, has been clarified to be linked with a putative precursor lesion designated as endometrial intraepithelial carcinoma (EIC) [2-4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The uterine endometrial polyp (EMP) has a potential risk of developing malignant tumors especially in postmenopausal women. These malignancies include endometrial intraepithelial carcinoma (EIC). Patients and methods Eight patients with EIC in the EMP, who were postmenopausal with ages ranging from 49 to 76 years (av. 62), were cytologically reviewed in comparison with histological findings. The endometrial cytological findings were summarized as follows: mucous and watery diathesis as a background lacking or with little necrotic inflammatory changes; micropapillary cluster formation; abrupt transition between carcinoma cells and normal cells; nuclear enlargement; high N/C ratio; and single or a few prominent nucleoli. Histologically, one case had EIC alone in the EMP; three cases had EIC with stromal invasion confined to the EMP; and four cases had EIC in the atrophic endometrium in addition to EIC in the EMP. Seven patients have taken a disease-free course after surgical resection, but one patient died 44 months following the initial diagnosis because of the massive tumor extending over her peritoneal cavity. Endometrial cytology may be helpful for the detection of early endometrial adenocarcinomas with serous features including EIC. Some early stage endometrial adenocarcinomas represented by EIC exceptionally take an aggressive clinical course irrespective of a lack of extrauterine lesions. Virtual Slides The virtual slide(s) for this article can be found here:
    Diagnostic Pathology 02/2013; 8(1):25. DOI:10.1186/1746-1596-8-25 · 2.60 Impact Factor
Show more